Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

If you are a current holder of COMS and would like additional information concerning this proposed transaction, including your rights, contact Hamilton Lindley at 877-744-3728 or by email at hlindley@kendalllawgroup.com. Kendall Law Group has substantial experience representing investors in mergers and acquisitions nationwide. Lawyers at the firm include a former United States Attorney, federal judicial law clerk, a former state and federal judge, in addition to experienced securities lawyers.

SOURCE: Kendall Law Group

Kendall Law Group LLP 
Hamilton Lindley, 214-744-3000 
877-744-3728 Toll Free 
214-744-3015 Facsimile 
hlindley@kendalllawgroup.com 
www.kendalllawgroup.com

Here are highlights from Thursday's Analyst Blog:

Hewlett-Packard to Acquire 3Com

Hewlett Packard Company (NYSE: HPQ) is planning to take over networking gear maker 3Com Corporation (Nasdaq: COMS). The acquisition, valued at $2.7 billion, enables HP to challenge networking leader Cisco Systems Inc. (Nasdaq: CSCO) on its own turf.

HP's current networking products, sold under the ProCurve brand, generate around $1 billion in annual sales (less than 1% of the company's total revenue). The product line lacks competitive data center switches, which makes it hard to take market share from well-entrenched Cisco.

3Com's expertise is in networking products for data centers, which supports HP's ProCurve networking equipment. Although the company has seen better times, it has been beefing up its portfolio by utilizing its design capabilities in low-cost China. The company is, therefore, in a position to compete aggressively on price. 3Com's challenges include its poor brand value in American and European markets and its weak position in these geographies.

The HP-3Com combination is therefore an ideal fit, in our opinion. If the deal closes, HP will acquire a new capability overnight, strengthen its position in China and grow at its competitor's expense. 3Com will benefit from HP's superior brand value and find a broader market for its new products.

Wal-Mart Sales Up in U.S., Europe

Wal-Mart Stores Inc. (NYSE: WMT) reported strong fiscal third-quarter earnings of 84 cents per share, which surpassed the Zacks Consensus Estimate of 81 cents. Earnings grew 9.1% year over year from 77 cents recorded in the year-ago quarter, and exceeded management's guidance of 78 cents to 82 cents per share.

Wal-Mart's net sales recorded a growth of 1.1% year over year to $98.7 billion, as a 1.2% expansion in Wal-Mart's U.S. segment coupled with a 1.6% increase in the International segment was partially offset by 0.7% decline in the Sam's Club segment. The growth in International sales was driven by robust performance in the U.K., Mexico and Brazil, but was limited by unfavorable currency fluctuations.

The retailing behemoth, widely considered as a barometer of the country's economy, said U.S. same-store sales dipped 0.5% year-over-year, while that for Sam's Club rose by 0.1%.

Glaxo Reports Higher Revenues

GlaxoSmithKline, plc (NYSE: GSK) reported third quarter income of 92 cents per American Depository Share (ADS), 3 cents below the Zacks Consensus Estimate. The company reported earnings of 94 cents in the year-ago period.

Third quarter 2009 revenue increased 3%, with growth being driven by strong performances in emerging markets (up 25%), Japan (up 19%) and Consumer Healthcare (up 8%). We were pleased to see growth in Consumer Healthcare revenue despite the global slowdown.

Meanwhile, US sales continued to be impacted by generic competition with revenue declining 12%. Sales of products like Imigran (down 74%), Lamictal (down 21%) and Requip (down 30%) and Wellbutrin XL (down 81%) kept declining.

Pharmaceutical product revenue increased 2% with sales being driven by Advair/Seretide (up 5%) and Relenza. Relenza benefited from continued orders from several governments for stockpiling.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5514.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5516

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com 
Mark Vickery 
Web Content Editor 
312-265-9380 
Visit: www.zacks.com

In an effort to prepare his readers for the remainder of 2009 and help them position their portfolios for the coming year, Next Inning has published McWilliams' Strategy Review and outlook for the next year. In this extensive report, McWilliams provides an in-depth forecast for a variety of tech sectors, points out what he sees as three danger periods looming in our future, and provides specific investment opinions and price targets on 37 leading tech stocks.

Long-term Next Inning readers know this is an important report. In his special report published in late 2008, he helped position readers early with big winners like Apple, Blue Coat Systems, Flextronics, 3Com and Sun Microsystems, noting clearly the latter two were acquisition candidates. Prices for these stocks have since advanced between 130% and 255%.

To get the inside scoop on how McWilliams regularly tops broad market performance, investors have the opportunity to take a free 21-day test drive with Next Inning. With this, investors will see firsthand how McWilliams has delivered a year-to-date return of 55% and will receive real-time access to his commentary. To take advantage of this offer, please visit the following link:

https://www.nextinning.com/subscribe/index.php?refer=prn912

McWilliams covers these topics and more in his recent reports:

-- McWilliams suggested buying 3Com when it was trading for only $2.12 last December. With Hewlett-Packard's offer to buy the company for nearly $8 on the table now, what does he think 3Com shareholders should do?

-- What trends does McWilliams think will impact the EMS (Electronic Manufacturing Services) sector during the coming year? What EMS companies does McWilliams think merit consideration today from investors? What are his fair value price targets for EMS leaders Benchmark, Celestica and Flextronics?

-- What are McWilliams' thoughts about the demand atmosphere for data center and WAN optimization products and what stocks does he think will be the big winners next year? With the price of Blue Coat Systems up over 240% since he suggested buying it last year, does he think there is more to come or that it has overshot its fair value? Does he see Blue Coat as a potential acquisition target?

Founded in September 2002, Next Inning's model portfolio has returned 206% since its inception versus 22% for the S&P 500.

About Next Inning:

Next Inning is a subscription-based investment newsletter that provides regular coverage on more than 150 technology and semiconductor stocks. Subscribers receive intra-day analysis, commentary and recommendations, as well as access to monthly semiconductor sales analysis, regular Special Reports, and the Next Inning model portfolio. Editor Paul McWilliams is a 30+ year semiconductor industry veteran.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, Next Inning Technology Research, +1-888-278-5515

SOURCE Indie Research Advisors, LLC

http://www.nextinning.com